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Do CARs Need a Driver’s License?
Adoptive Cell Therapy with Chimeric Antigen
Receptor-Redirected T Cells Has Caused
Serious Adverse Events
Hildegard Bu¨ning,1 Wolfgang Uckert,2 Klaus Cichutek,3 Robert E. Hawkins,4 and Hinrich Abken1
Metastatic cancer still remains difficult to treat; al-though most new agents are of clear palliative benefit
for the majority of patients, they frequently do not control
cancer in the long term. Immunotherapy, by contrast, can
result in long-term benefits even after short-term treatment. In
particular, adoptive transfer of autologous tumor-infiltrating
lymphocytes (TILs) in combination with a nonmyeloablative
lymphodepletion regimen has resulted in greater than 70%
response rates in melanoma, with proven durability at least in
some cases (Dudley et al., 2005, 2008). Although these and
other data indicate the potential of adoptive cell therapy, the
strategy is technically challenging: first, TILs must be isolated
from surgical tumor specimens, which is particularly difficult
in the case of solid tumors, and second, tumor-reactive T cells
must be identified and expanded to sufficient numbers for
therapeutic application. The procedure can be simplified by
ex vivomodification of primary human lymphocytes from the
cancer patient with a recombinant receptor molecule, such as
a chimeric antigen receptor (CAR), of predefined specificity
for cancer cells (Eshhar, 2008; Vera et al., 2009). The chimeric
antigen receptor is composed of an extracellular, antibody-
derived antigen-binding domain fused to an intracellular,
T cell receptor (TCR)-derived CD3z domain to provide T cell
activation on engagement of antigen. By using an antibody for
binding, CAR recognition of antigen becomes independent of
antigen processing and presentation by the major histocom-
patibility complex, both frequently altered in tumors, and is
moreover suitable for recognition of nonclassical T cell anti-
gens including carbohydrates.
Although cytotoxic T lymphocytes (CTLs) engineered
with a tumor-associated antigen-specific CAR induced
tumor cell lysis in vitro and eradicated transplanted tumors
in a variety of mouse models, in the first clinical trials the
therapeutic efficacy of CAR-engineered T cells was limited
(Kershaw et al., 2006; Lamers et al., 2006; Till et al., 2008). This
was thought to be due to transient T cell activation and poor
in vivo persistence due to the lack of the second (costimula-
tory) signal, which is necessary—in addition to TCR signaling—
to evade anergy induction. Second-generation CARs conse-
quently possess a costimulatory moiety derived from CD28,
OX40 (CD134), or 4-1BB (CD137) together with CD3z in the
intracellular domain to improve T cell activation and ex-
pansion. To further improve T cell activation and persistence,
the CD28 and 4-1BB domains were subsequently combined,
leading to third-generation CARs (Carpenito et al., 2009;
Zhao et al., 2009).
An increasing number of clinical trials are currently eval-
uating second- and third-generation CARs in the treatment
of malignant diseases. Although some of them produced
encouraging preliminary evidence of clinical efficacy
(Brentjens et al., 2010a), two serious adverse events (SAEs)
were reported. In the trial performed by the Surgery Branch
at the National Institutes of Health (NIH, Bethesda, MD), a
patient with refractory colon cancer with lung and liver
metastases received, after nonmyeloablative lymphodeple-
tion, 1010 T cells engineered with an anti-ErbB2 third-
generation CAR allowing for CD28 and 4-1BB costimulation
(Morgan et al., 2010). Immediately after infusion the patient
developed dramatic pulmonary toxicity with lung infiltrates
and a cytokine storm with increased levels of interferon
(IFN)-g, granulocyte-macrophage colony-stimulating factor
(GM-CSF), tumor necrosis factor (TNF)-a, interleukin (IL)-6,
and IL-10 followed by cardiac arrest. The patient died on day
5 after treatment. On the basis of extensive postmortem an-
alyses the investigators concluded that the toxicity was likely
due to the accumulation of a large number of modified T cells
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in the lung and their cytokine release on binding to ErbB2,
which is physiologically expressed at low levels on lung
epithelia. The second SAE occurred in the trial performed at
the Memorial Sloan-Kettering Cancer Center (New York,
NY): an extensively pretreated, lymphodepleted patient with
chronic lymphocytic leukemia (CLL) developed hypoten-
sion, dyspnea, and fever after infusion of T cells engineered
with an anti-CD19 second-generation CAR containing the
CD28 domain at a total dose of 3107 T cells/kg. In contrast
to patients in the first cohort of the trial, who received the
same number of T cells without developing significant ad-
verse events, this patient was the first to receive a cyclo-
phosphamide pretreatment for lymphodepletion followed by
T cell infusion. The autopsy did not reveal an obvious cause
of death; however, investigators assume that low-grade
sepsis present before T cell infusion may have triggered the
observed elevated cytokine levels and that cyclophospha-
mide used for lymphodepletion may have mediated a cyto-
kine storm, which in turn boosted activation of transferred
modified T cells. The immune-modulatory effect of cyclo-
phosphamide in this context is probably multifactorial
and several, mutually nonexclusive mechanisms may be
envisaged: enhanced homeostatic expansion of modified
T cells by the creation of a niche; induction of T cell growth
factors including type I interferons; stimulation of innate
immune cells, particularly dendritic cells; and elimination of
regulatory T cells. Although these proposed mechanisms are
still controversial, they have each been proposed on the basis
of specific models in which cyclophosphamide was injected
into tumor-bearing hosts before adoptive transfer of in vitro-
expanded tumor-specific T cells (Dudley et al., 2005).
While the CARs used in these trials showed efficient an-
titumor activity in mouse models (Brentjens et al., 2007; Zhao
et al., 2009), autoreactivity may be difficult to predict, in
particular if it varies from patient to patient. However, re-
directed activation of T cells obviously needs to be better
tuned in vivo, a drawback that is currently impaired by a
number of factors. In the following we discuss some draw-
backs and potential solutions.
Adoptive transfer of CAR-engineered T cells is thought to
be a specific targeting approach defined by the antibody-
derived binding domain of the CAR. However, apart from B
lymphoma idiotypes, CAR-targeted antigens are frequently
found on healthy tissue, although expressed at lower levels.
As a consequence, CAR-directed T cell attack on healthy
tissue may result in severe toxicity (‘‘on-target off-organ’’
toxicity). Even short-term T cell persistence seems to be
sufficient to produce significant toxicity as evident from
studies with first-generation CAR-modified T cells. For
instance T cells modified with a first-generation CAR specific
for carbonic anhydrase IX, expressed on renal cell carcinoma,
induced reversible yet discrete cholangitis and damage to
bile duct epithelium due to target antigen expression on
those cells, although at low levels (Lamers et al., 2006). T cells
modified with a MART-1 (melanoma antigen recognized by
T cells)-specific TCR induced inner ear and retina toxicity
due to antigen expression in these organs at similar levels as
on targeted melanoma cells ( Johnson et al., 2009). These ex-
amples highlight the need to discriminate between tumor
cells expressing the antigen at a high level and those cells
with physiological medium- or low-level expression of the
same antigen. As discrimination is, at least in part, impacted
by the CAR binding affinity/avidity, use of low-affinity
antibodies may overcome this problem.
Currently used CAR binding domains are derived from
high-affinity antibodies or are optimized for high-affinity
binding. In the NIH trial the CAR binding domain was
based on the widely used humanized antibody trastuzumab
(Herceptin) and had a high binding affinity, that is,
KD¼ 0.3 nM (Zhao et al., 2009). Hence, CAR binding af-
finity was much higher than the avidity of the physiolog-
ical TCR. High-affinity binding, however, is less
discriminative between moderate and high antigen
amounts on target cells, resulting in CAR-triggered T cell
activation also on binding to cells with moderate antigen
levels, as found on healthy tissues. An increase in binding
affinity above threshold thereby does not increase T cell
activation with respect to cytokine release and cytolysis,
which would be advantageous for immunotherapeutic
approaches, but results in a loss of selectivity for high-level
antigen-expressing targets (Chmielewski et al., 2005).
Consequently, moderate- or even low-affinity CARs that
need higher antigen levels to efficiently trigger T cell ac-
tivation may target more selectively tumor cells with high
antigen load.
Combining CD3z and costimulation allowed the limited
efficacy of first-generation CARs to be overcome and im-
proved cytokine secretion and cytolytic activity. The CAR in
the NIH trial was combined with CD28 and 4-1BB co-
stimulatory molecules, whereas in the Sloan-Kettering trial
CD28 costimulation was used to improve T cell activation. In
the NIH trial a lethal cytokine storm occurred immediately
after T cell infusion, whereas the cytokine storm in other
trials, such as the Rotterdam trial (Lamers et al., 2006), oc-
curred hours or days later. Forced CD28 costimulation as it
occurs by combined CD28 and 4-1BB costimulation may
predestine the recipient for a cytokine storm, as does ad-
ministration of the superagonistic anti-CD28 antibody
(Suntharalingam et al., 2006). An alternative, perhaps more
manageable approach for providing the costimulatory signal
is to express a first-generation CAR in the absence of costim-
ulatory domains on virus-specific T cells, which then receive
costimulation by antigen engagement through their native
TCR on antigen-presenting cells (APCs) (Cooper et al., 2005;
Pule et al., 2008). This strategy is supported by a trial (Pule
et al., 2008) in which selected Epstein–Barr virus (EBV)-specific
T cells modified with a neuroblastoma-associated antigen-
specific CAR showed longer in vivo persistence than un-
selected T cells with the same CAR that did not receive
costimulation by EBV antigen-presenting cells.
Other domains within CARs may also affect ‘‘off-target’’
activation. Some trials currently in planning use the IgG1
CH2–CH3 domain as a spacer in the extracellular moiety
between the binding and transmembrane domains to im-
prove CAR expression and target binding. This particular
IgG1 spacer, however, has been shown to bind to Fc receptor-
expressing cells in vitro, including monocytes and natural
killer (NK) cells, leading to their activation and release of
proinflammatory cytokines (Hombach et al., 2010). CAR-
modified T cells may also become activated through CAR
cross-linking by Fc receptor binding, which results in cyto-
kine release and cytolysis of the engaged cells. This process
may contribute to initiate an ‘‘off-organ’’ innate response and
to sustain a cytokine storm. The side effect may be reduced
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by modifying the IgG1 spacer domain to reduce Fc receptor
binding (Hombach et al., 2010). The issue of IgG spacer-
associated ‘‘off-target’’ activation, however, does not hold
true for the NIH trial, which used a CD8 hinge, or for the
Sloan-Kettering trial, in which the CAR binding domain was
directly linked to the CD28 transmembrane moiety.
The dose at which T cells are administered is, moreover,
crucial for first trials conducted in humans. A more restricted
dose escalation scheme for initial studies in humans, starting
with doses that are unlikely to cause serious toxicity, is re-
commended by investigators in the NIH study (Morgan et al.,
2010). First infusion of low-dose T cells or prolonged infusion
over 2 days, with one-third given the first day and two-thirds
the second day, as in the modified Sloan-Kettering trial
(Brentjens et al., 2010b), may prevent the immediate onset of
severe adverse events. Both strategies will help to define the
therapeutic window; in addition, low numbers of infused
T cells need more time to expand to numbers that may cause
severe toxicity, giving more time for therapeutic interven-
tions. Modified T cells targeting antigens in those organs to
which they nonspecifically localize immediately after infu-
sion, such as the lungs and liver, may more rapidly cause
SAEs than T cells targeting antigens on organs that are later
and less efficiently infiltrated. Apart from that, administra-
tion to a single patient followed by a suitable waiting period
and other measures described in the guidelines for first use
of novel medicinal products in humans should generally be
considered.
Once SAEs became clinically apparent in the Rotterdam
trial, steroids were administered to stop the autoaggression
and to eliminate most of the modified T cells in circulation
(Lamers et al., 2006). Steroid application is generally effective,
as demonstrated in allogeneic donor lymphocyte infusions to
abrogate graft-versus-host disease (Ciceri et al., 2009). In
addition, T cells can be engineered with a herpes simplex
virus thymidine kinase (TK) gene to allow elimination of
modified T cells by application of nucleoside prodrugs. Ex-
perimental models, however, imply limited safety due to
insufficient kinase activity, which can be partially compen-
sated by coexpression of a second suicide gene (Uckert et al.,
1998). Alternatively, inducible caspase-9 has been expressed
in CAR-modified T cells to cause apoptosis, which is brought
about by administration of a dimerizer that forms the active
enzyme from two nonfunctional molecules (Tey et al., 2007;
de Witte et al., 2008). CD19-specific CAR-engineered T cells
have been modified with inducible caspase-9 to improve
safety (Hoyos et al., 2010). T cells engineered with a Myc tag
incorporated in the transgenic TCR a-chain were efficiently
eliminated in an experimental mouse system by adminis-
tration of a depleting anti-Myc antibody (Kieback et al.,
2008). This safeguard has the advantage that it does not
depend on high-level expression of a second transgene be-
sides the CAR, and the elimination is specific and not toxic to
other cells. An alternative strategy is based on transient CAR
expression in modified T cells, instead of the stable expres-
sion achieved with the commonly used retro- or lentiviral
vectors. Coding RNA is transferred by electroporation into
T cells, which subsequently express CARs and execute re-
directed cytolytic functions toward target cells (Birkholz et al.,
2009). The expanding RNA-modified T cells gradually lose
CAR expression, with a half-life of about 2 days, whereas
nonactivated T cells continue to express CARs for several
days in vitro. Transient CAR expression will thereby be of
advantage in exploring immediate toxicity in initial human
applications. Of course, the efficacy of this approach must be
clinically tested to ensure that the intended effect can be
achieved in humans.
Great credit must be given to the investigators in both
trials for presenting detailed reports to the scientific com-
munity, which will help to make CAR-redirected T cell
therapy safer in the treatment of cancer.
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